Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacutamab with GemOx versus GemOx alone in relapsed or refractory KIR3DL2-positive peripheral T-cell lymphoma
2020-003735-16Phase 2Active
- Sponsor
- LYSARC
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lacutamab in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and 8 more (2 arms), sponsored by LYSARC. Primary endpoint: median modified progression-free survival. Started Apr 2021; status: active.
02
Drugs
lacutamab
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)T-cell lymphoma follicular helper (TFHL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2020-003735-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003735-16.